CAR-T Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | AbbVie Inc., Amgen, Inc., Atara Biotherapeutics, Inc., Autolus Therapeutics PLC., bluebird bio, Celgene, Gilead

April 14 21:20 2021
CAR-T Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | AbbVie Inc., Amgen, Inc., Atara Biotherapeutics, Inc., Autolus Therapeutics PLC., bluebird bio, Celgene, Gilead

CAR-T Pipeline

CAR-T is a type of treatment in which a patient’s T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient’s blood. Then the gene for a special receptor that binds to a certain protein on the patient’s cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion. CAR T-cell therapy is used to treat certain blood cancers, and it is being studied in the treatment of other types of cancer. Also called chimeric antigen receptor T-cell therapy.

DelveInsight’s, CAR-T Pipeline Insights, 2021,” report provides comprehensive insights about 250+ companies and 250+ pipeline drugs in CAR-T pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

 

Get free sample report: https://www.delveinsight.com/sample-request/car-t-pipeline-insight

 

Some of the CAR-T Companies:

  • AbbVie Inc.
  • Adaptimmune Therapeutics PLC.
  • Amgen, Inc.
  • Atara Biotherapeutics, Inc.
  • Aurora Biopharma, Inc.
  • Autolus Therapeutics PLC.
  • Bellicum Pharmaceuticals, Inc.
  • BioAtla LLC.
  • bluebird bio
  • Carina Biotech
  • CARsgen Therapeutics, Ltd.
  • CARTherics
  • Celgene
  • Cellectis
  • Celularity
  • Celyad SA
  • Creative Biolabs
  • DiaCarta, Inc.
  • Endocyte, Inc.
  • F1 Oncology, Inc.
  • Fate Therapeutics Inc.
  • Gilead
  • Humanigen, Inc.
  • Immune Therapeutics, Inc.
  • Intrexon, Corp.
  • Juno Therapeutics, Inc.
  • Kite Pharma, Inc.
  • Lion TCR Pte Ltd.
  • MaxCyte, Inc.
  • Mesoblast, Ltd.
  • Minerva Biotechnologies Corp.
  • Mustang Bio, Inc.
  • Novartis AG
  • Oxford BioMedica PLC.
  • PeproMene Bio Inc.
  • Pfizer, Inc.
  • Posedia Therapeutics Inc.
  • Precision Biosciences, Inc.
  • ProMab Biotechnologies Inc.
  • Servier Oncology
  • Sorrento Therapeutics, Inc.
  • TC Biopharm Ltd.
  • Tessa Therapeutics Pte Ltd.
  • TILT Biotherapeutics Ltd.
  • Tmunity Therapeutics Inc.
  • TrakCel Ltd.
  • Xyphos
  • ZIOPHARM Oncology, Inc.
  • And Many Others

 

Get free sample report: https://www.delveinsight.com/sample-request/car-t-pipeline-insight

 

Some of the CAR-T Therapies:

  • LCAR-B38M CAR-T Cell
  •  Anti-CEA CAR-T cells
  •  CD30.CAR-T
  •  AUTO CAR T cell therapy
  •  Defibrotide
  •  MB-CART2019.1 Dose level 1
  •  CAR-T
  •  CD19/22 CART
  •  JNJ-68284528
  •  CD123 CAR-T cells
  •  CD19 CAR-T cells
  •  BCMA CAR-T cells
  •  CEA CAR-T cells
  •  CAR-T cell immunotherapy
  •  Autologous CAR-T cells
  •  Second generation CAR-T cells
  •  CAR-T/TCR-T cells immunotherapy
  •  Allogeneic hematological stem cell transplantation
  •  Humanized CD19 CAR-T cells
  •  CD19 CART
  •  MB-CART20.1
  •  MB-CART19.1
  •  IM19 CAR-T Cells
  •  CLDN6 CAR-T
  •  Autologous CD19-targeting CAR T cells
  •  P-BCMA-101 CAR-T cells
  •  MLM-CAR44.1 T-cells, cyclophosphamide and fludarabine from -5 to -3
  •  CART-19/22
  •  Anakinra
  •  Anti-MUC1 CAR-T cells
  •  CAR T-cell therapy
  •  CAR T cells
  •  CART-19
  •  CAR-CD19 T Cells
  •  CAR-BCMA T Cells
  •  LCAR-B38M CAR-T cell injection
  •  AUTO1
  •  AUTO3
  • And Many Others

 

Get free sample report: https://www.delveinsight.com/sample-request/car-t-pipeline-insight

 

Table of Contents:

Introduction

Executive Summary

CAR-T: Overview

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

CAR-T – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

• CAR-T companies’ collaborations, Licensing, Acquisition -Deal Value Trends

CAR-T Collaboration Deals

Late Stage Products (Phase II)

• Comparative Analysis

JNJ-68284528: Janssen Research & Development, LLC

Mid Stage Products (Phase II)

• Comparative Analysis

LCAR-B38M CAR-T Cell: Nanjing Legend Biotech Co.

CD30.CAR-T: Tessa Therapeutics

Early Stage Products (Phase I)

• Comparative Analysis

IM21 CAR-T cells: Beijing Immunochina Medical Science & Technology Co., Ltd.

Pre-clinical and Discovery Stage Products

• Comparative Analysis

Research programme: CAR-T cell therapy – Endocyte/Seattle Childrens Research Institute

Research programme: chimeric antigen receptor T cell therapies – CRISPR Therapeutics

Inactive Products

Comparative Analysis

CAR-T- Market Drivers and Barriers

Appendix

 

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/car-t-pipeline-insight

  Categories: